USA Dr David J. Rawlings is the division head of immunology at Seattle Children’s and director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. An immunologist and rheumatologist working at the forefront of cell engineering, his research focuses on therapies that modulate immune responses across cancer, genetic…
Australia Medicines regulatory agencies face enormous challenges in supporting and maintaining the safety, quality and supply of therapeutic goods in their respective countries and regions. Professor Anthony (Tony) Lawler, head of Australia’s Therapeutic Goods Administration (TGA), took time out from this work to respond to questions regarding the progress that TGA is…
UAE Prof. Fatma Al Jasmi, Professor of Biochemical Genetics at the UAE University’s College of Medicine & Health Science and the UAE’s first biochemical genetics consultant, has spent nearly two decades building a rare and genetic disease infrastructure from the ground up. Prof. Al Jasmi traces that journey – from persuading…
Taiwan Hans Duijf, General Manager of Novo Nordisk Taiwan, has spent his entire 28-year career with the Danish pharmaceutical company, a rare tenure in today’s era of executive mobility. Duijf has led affiliates across several regions before arriving in Taiwan eight months ago. A committed advocate of the company’s triple bottom…
USA Successive American governments have grappled with the need to contain spiraling healthcare costs while sustaining the USA’s well-earned reputation as the number one launch market for breakthrough medical innovations. “The most difficult question of our time in our sector relates to how to fund access to advanced therapies,” explains Marwan…
Europe The European Health Data Space (EHDS) is a landmark regulation designed to unify health data across the EU for both direct patient care and medical research. Writing in the April 2026 edition of DIA’s Global Forum magazine, Tom Brookland, Pascal Hofer, and Didier Pomeranc of Roche explain that while the…
MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…
China Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for the future of access and innovation in the world’s second largest market. With the tremendous development of China’s innovative…
USA Katherine Stueland, CEO of GeneDx, describes transforming the 26-year-old NIH spinout into a scalable, patient-focused business. Leveraging the Infinity database, strategic biopharma partnerships, AI-driven interpretation, and cost-efficient exome and genome testing, GeneDx accelerates rare disease diagnosis. The company is aiming to assist in the expansion of newborn screening programs as…
Hong Kong Anirvan Dutt Chaudhuri, General Manager of Novo Nordisk Hong Kong, brings nearly 15 years of commercial leadership experience across global markets including Denmark, Switzerland, the US, Turkey, and now Hong Kong. Since arriving in 2024, he has transformed the local affiliate by building critical functions, expanding cross-border collaboration, and driving…
USA Matt Heck, founder and CEO of Sentynl Therapeutics, outlines the company’s acquisition-led rare disease strategy following its integration into Zydus Group in 2017. He discusses building a focused portfolio of life-extending paediatric therapies, leveraging orphan drug incentives, prioritising early diagnosis, expanding internationally, and partnering closely with patient foundations to maximise…
Hong Kong Roche Diagnostics Hong Kong is entering a defining phase as the city accelerates its shift toward primary care, early detection and data-driven decision making. In this interview, General Manager Ronald Lo reflects on eighteen months of strategic progress, from expanding point-of-care testing and preparing breakthrough Alzheimer’s‑related biomarkers to shaping regulatory…
See our Cookie Privacy Policy Here
